コムラ　カズマサ   Kazumasa Komura   小村　和正    所属   川崎医科大学  医学部 臨床医学　泌尿器科学    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact.
掲載誌名	正式名：World journal of urology 略　 称：World J Urol ISSNコード：14338726/07244983
掲載区分	国外
巻・号・頁	43(1),pp.135
著者・共著者	Tatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, Kiyoshi Takahara, Kazumasa Komura, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Takahiro Adachi, Yosuke Hirasawa, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Tatsushi Kawada, Satoshi Katayama, Kengo Iwatsuki, Ko Nakamura, Kyosuke Nishio, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Ryoichi Maenosono, Taizo Uchimoto, Tomoaki Takai, Takeshi Hashimoto, Teruo Inamoto, Kazutoshi Fujita, Motoo Araki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
発行年月	2025/02
概要	PURPOSE:The purpose of this study is to determine the utility of the CANLPH score as a predictive biomarker for patients with advanced and metastatic renal cell carcinoma (a/mRCC). By validating its prognostic value, this study aims to contribute to more personalized treatment strategies for a/mRCC.METHODS:In a multicenter retrospective study by the JK-FOOT consortium, we analyzed data from 309 a/mRCC patients undergoing ICI-based therapy. The CANLPH score-a composite marker of C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR), and platelet to hemoglobin ratio (PHR)-for its prognostic accuracy in predicting cancer-specific survival (CSS). Advanced statistical methods, including receiver operating characteristic (ROC) curve analysis, Cox proportional-hazard regression, and Harrell's concordance index (C-index), were employed to assess its predictive capacity against established factors.RESULTS:The median follow-up period was 17 months, revealing two-year and five-year overall survival rates of 76.8% and 62.4%, respectively, with CSS rates at 78.3% and 66.2%. The CANLPH score well stratified survival outcomes of ICI-based treatment for RCC patients (HR 5.71; P < 0.0001). C-index analysis demonstrated that the CANLPH score had the highest predictive potency for CSS among models, including IMDC score. Multivariate analysis confirmed the CANLPH score (HR, 5.59; P = 0.0007) and Karnofsky performance status (HR, 2.59; P = 0.0032) as independent prognostic factors for CSS.CONCLUSIONS:The CANLPH score emerges as a critical tool in the a/mRCC therapeutic landscape, enabling precise prediction of patient outcomes with ICI-based therapies. Limitations include the retrospective design and the single national cohort. Prospective validation studies are warranted.
DOI	10.1007/s00345-025-05507-6
PMID	39992409